Hantz Financial Services, Inc. Northwest Biotherapeutics Inc Transaction History
Hantz Financial Services, Inc.
- $5.63 Billion
- Q3 2024
A detailed history of Hantz Financial Services, Inc. transactions in Northwest Biotherapeutics Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 250 shares of NWBO stock, worth $67. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250
Previous 250
-0.0%
Holding current value
$67
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NWBO
# of Institutions
13Shares Held
674KCall Options Held
0Put Options Held
0-
Moloney Securities Asset Management, LLC462KShares$124,7980.02% of portfolio
-
Opus Capital Group, LLC60.2KShares$16,2400.0% of portfolio
-
Williams Jones Wealth Management, Llc. New York, NY35KShares$9,4500.0% of portfolio
-
Ethos Financial Group, LLC King Of Prussia, PA23.7KShares$6,3990.0% of portfolio
-
Lee Danner & Bass Inc20KShares$5,4000.0% of portfolio
About NORTHWEST BIOTHERAPEUTICS INC
- Ticker NWBO
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 1,037,230,016
- Market Cap $280M
- Description
- Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, wh...